kabutan

ONO PHARMA, Apr-Dec (Cumulative 3Q) Net Income Decreases by 49%, Oct-Dec Net Income Decreases by 59%

Mon Feb 3, 2025 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on February 3rd. The consolidated net income for the cumulative third quarter of the fiscal year ending March 2025 (April to December) dropped 48.8% from the same period last year to 56.5 billion yen. The progress rate toward the full-year plan of 58 billion yen was 97.6%, also surpassing the five-year average of 85.3%.

Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to significant drop 91.9% from the same period last year to 1.4 billion yen.

In the most recent three-month period, from October to December (3Q), the consolidated net income significantly dropped to 14.9 billion yen, a 58.5% decrease compared to the same period last year. The operating profit margin sharply declined from 36.3% in the same period last year to 11.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Dec, 2022 339,020 122,590 124,379 95,656 195.9 86.7 Jan 31, 2023 IFRS
Apr - Dec, 2023 389,903 144,626 147,292 110,544 229.1 90.0 Jan 31, 2024 IFRS
Apr - Dec, 2024 374,562 70,754 72,037 56,592 120.5 88.4 Feb 3, 2025 IFRS
YoY -3.9% -51.1% -51.1% -48.8% -47.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 243,959 62,899 64,438 53,486 111.4 40 May 9, 2024 IFRS
Oct - Mar, 2024 Guidance 244,661 33,212 33,956 20,565 43.8 40 Oct 31, 2024 IFRS
YoY +0.3% -47.2% -47.3% -61.6% -60.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 447,187 141,963 143,532 112,723 230.9 70 May 10, 2023 IFRS
Mar, 2024 502,672 159,935 163,734 127,977 266.6 80 May 9, 2024 IFRS
Mar, 2025 Guidance 485,000 82,000 81,500 58,000 123.5 80 Oct 31, 2024 IFRS
YoY -3.5% -48.7% -50.2% -54.7% -53.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2023 131,190 47,590 47,996 36,053 74.7 36.3 Jan 31, 2024 IFRS
Jan - Mar, 2024 112,769 15,309 16,442 17,433 36.3 13.6 May 9, 2024 IFRS
Apr - Jun, 2024 117,675 30,690 33,310 24,794 52.8 26.1 Jul 31, 2024 IFRS
Jul - Sep, 2024 122,664 18,098 14,234 12,641 26.9 14.8 Oct 31, 2024 IFRS
Oct - Dec, 2024 134,223 21,966 24,493 19,157 40.8 16.4 Feb 3, 2025 IFRS
YoY +2.3% -53.8% -49.0% -46.9% -45.4%

Related Articles